Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Mini-Review Article

血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂是胰腺癌潜在的治疗选择

卷 22, 期 10, 2022

发表于: 13 July, 2022

页: [785 - 795] 页: 11

弟呕挨: 10.2174/1568009622666220517104411

价格: $65

摘要

肾素-血管紧张素系统(RAS)已被报道在致癌过程中发挥作用，因此它可能是抑制肿瘤生长的潜在治疗靶点。已有研究表明，通过血管紧张素I转换酶抑制剂(ACEIs)和血管紧张素II型1受体抑制剂(ARBs)抑制RAS可能对几种恶性肿瘤有保护作用。在这里，我们概述了RAS途径和通过ACE/ARB抑制剂靶向胰腺癌的潜在价值。虽然RAS作为胰腺癌治疗靶点的潜在作用已被报道，但坎地沙坦与吉西他滨联合使用未能改善胰腺癌的预后。另一项使用ARB 1-3年的研究发现，它可以降低胰腺癌的风险。与这些试验一致的是，其他研究表明ARB联合吉西他滨可能改善晚期胰腺癌患者的临床结果。有必要进行前瞻性试验来调查这一假设。

关键词: 胰腺癌，ACE抑制剂，ARB抑制剂，肾素-血管紧张素系统，致癌，吉西他滨。

Next »
图形摘要

[1]
Lanfredini, S.; Thapa, A.; O’Neill, E. RAS in pancreatic cancer. Biochem. Soc. Trans., 2019, 47(4), 961-972.
[http://dx.doi.org/10.1042/BST20170521] [PMID: 31341034]
[2]
McGuigan, A.; Kelly, P.; Turkington, R.C.; Jones, C.; Coleman, H.G.; McCain, R.S. Pancreatic cancer: A review of clinical diagnosis, epi-demiology, treatment and outcomes. World J. Gastroenterol., 2018, 24(43), 4846-4861.
[http://dx.doi.org/10.3748/wjg.v24.i43.4846] [PMID: 30487695]
[3]
Mizrahi, J.D.; Surana, R.; Valle, J.W.; Shroff, R.T. Pancreatic cancer. Lancet, 2020, 395(10242), 2008-2020.
[http://dx.doi.org/10.1016/S0140-6736(20)30974-0] [PMID: 32593337]
[4]
Loveday, B.P.T.; Lipton, L.; Thomson, B.N.J. Pancreatic cancer: An update on diagnosis and management. Aust. J. Gen. Pract., 2019, 48(12), 826-831.
[http://dx.doi.org/10.31128/AJGP-06-19-4957] [PMID: 31774983]
[5]
Neoptolemos, J.P.; Kleeff, J.; Michl, P.; Costello, E.; Greenhalf, W.; Palmer, D.H. Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat. Rev. Gastroenterol. Hepatol., 2018, 15(6), 333-348.
[http://dx.doi.org/10.1038/s41575-018-0005-x] [PMID: 29717230]
[6]
Hashemzehi, M.; Beheshti, F.; Hassanian, S.M.; Ferns, G.A.; Khazaei, M.; Avan, A. Therapeutic potential of renin angiotensin system inhibitors in cancer cells metastasis. Pathol. Res. Pract., 2020, 216(7), 153010-153010.
[http://dx.doi.org/10.1016/j.prp.2020.153010] [PMID: 32534713]
[7]
Pinter, M.; Jain, R.K. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci. Transl. Med., 2017, 9(410), 9.
[http://dx.doi.org/10.1126/scitranslmed.aan5616] [PMID: 28978752]
[8]
George, A.J.; Thomas, W.G.; Hannan, R.D. The renin-angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer, 2010, 10(11), 745-759.
[http://dx.doi.org/10.1038/nrc2945] [PMID: 20966920]
[9]
van der Knaap, R.; Siemes, C.; Coebergh, J.W.; van Duijn, C.M.; Hofman, A.; Stricker, B.H. Renin-angiotensin system inhibitors, angio-tensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam Study. Cancer, 2008, 112(4), 748-757.
[http://dx.doi.org/10.1002/cncr.23215] [PMID: 18181094]
[10]
Afsar, B.; Afsar, R.E.; Ertuglu, L.A.; Kuwabara, M.; Ortiz, A.; Covic, A.; Kanbay, M. Renin-angiotensin system and cancer: Epidemiology, cell signaling, genetics and epigenetics. Clin. Transl. Oncol., 2021, 23, 682-696.
[http://dx.doi.org/10.1007/s12094-020-02488-3]
[11]
Deshayes, F.; Nahmias, C. Angiotensin receptors: A new role in cancer? Trends Endocrinol. Metab., 2005, 16(7), 293-299.
[http://dx.doi.org/10.1016/j.tem.2005.07.009] [PMID: 16061390]
[12]
Liao, Y.D.; Xu, H.; Han, Q.; Lei, J.; Zhang, Y.Y.; Wang, Z.H. Expression of angiotensin II type 1 receptor in cervical squamous cell carci-noma and its clinical significance. Zhonghua Zhong Liu Za Zhi, 2007, 29(5), 360-364.
[PMID: 17892132]
[13]
Peng, M.Y.; Wang, L.L.; Liang, T.; Zhao, X.L.; Wang, G.P.; Chen, F.P. Expression of angiotensin-II type 1 receptor at1 mRNA in myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2010, 18(6), 1418-1421.
[PMID: 21176342]
[14]
Wegman-Ostrosky, T.; Soto-Reyes, E.; Vidal-Millán, S.; Sánchez-Corona, J. The renin-angiotensin system meets the hallmarks of cancer. J. Renin Angiotensin Aldosterone Syst., 2015, 16(2), 227-233.
[http://dx.doi.org/10.1177/1470320313496858] [PMID: 23934336]
[15]
Sipahi, I.; Debanne, S.M.; Rowland, D.Y.; Simon, D.I.; Fang, J.C. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol., 2010, 11(7), 627-636.
[http://dx.doi.org/10.1016/S1470-2045(10)70106-6] [PMID: 20542468]
[16]
Collaboration, A.T. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 indi-viduals. J. Hypertens., 2011, 29(4), 623-635.
[http://dx.doi.org/10.1097/HJH.0b013e328344a7de] [PMID: 21358417]
[17]
Sipahi, I.; Chou, J.; Mishra, P.; Debanne, S.M.; Simon, D.I.; Fang, J.C. Meta-analysis of randomized controlled trials on effect of angioten-sin-converting enzyme inhibitors on cancer risk. Am. J. Cardiol., 2011, 108(2), 294-301.
[http://dx.doi.org/10.1016/j.amjcard.2011.03.038] [PMID: 21600543]
[18]
Pasternak, B.; Svanström, H.; Callréus, T.; Melbye, M.; Hviid, A. Use of angiotensin receptor blockers and the risk of cancer. Circulation, 2011, 123, 1729-1736.
[19]
Datzmann, T.; Fuchs, S.; Andree, D.; Hohenstein, B.; Schmitt, J.; Schindler, C. Systematic review and meta-analysis of randomised con-trolled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur. J. Intern. Med., 2019, 64, 1-9.
[http://dx.doi.org/10.1016/j.ejim.2019.04.019] [PMID: 31060961]
[20]
Dong-Mei, L.; Wei, Z.; Guang-Jun, H.; Lu, J.; Jian-Lun, H.; Jian, Z. Drugs affecting renin-angiotensin-aldosterone system and the cancer risk: A meta-analysis of nested case-control studies. Pak. J. Pharm. Sci., 2021, 34(1), 35-39.
[PMID: 34248000]
[21]
Song, T.; Choi, C.H.; Kim, M.K.; Kim, M.L.; Yun, B.S.; Seong, S.J. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. Eur. J. Cancer Prev., 2017, 26, 78-85.
[22]
Li, X.Y.; Sun, J.F.; Hu, S.Q. The renin-angiotensin system blockers as adjunctive therapy for cancer: A meta-analysis of survival out-come. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(6), 1375-1383.
[PMID: 28387887]
[23]
Sun, H.; Li, T.; Zhuang, R.; Cai, W.; Zheng, Y. Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies. Medicine (Baltimore), 2017, 96(13), e6394-e6394.
[http://dx.doi.org/10.1097/MD.0000000000006394] [PMID: 28353566]
[24]
Asgharzadeh, F.; Hashemzehi, M.; Moradi-Marjaneh, R.; Hassanian, S.M.; Ferns, G.A.; Khazaei, M.; Avan, A. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis. Life Sci., 2020, 242, 117181-117181.
[http://dx.doi.org/10.1016/j.lfs.2019.117181] [PMID: 31863771]
[25]
Zhou, Q.; Chen, D-S.; Xin, L.; Zhou, L-Q.; Zhang, H-T.; Liu, L.; Yuan, Y-W.; Li, S-H. The renin-angiotensin system blockers and survival in digestive system malignancies: A systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(7), e19075-e19075.
[http://dx.doi.org/10.1097/MD.0000000000019075] [PMID: 32049809]
[26]
Chen, X.; Yi, C.H.; Ya, K.G. Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta anal-ysis. J. Renin Angiotensin Aldosterone Syst., 2020, 21(3)1470320319895646
[http://dx.doi.org/10.1177/1470320319895646] [PMID: 32627649]
[27]
Asgharzadeh, F.; Jafarzadeh-Esfehani, R.; Hassanian, S.M.; Ferns, G.A.; Avan, A.; Khazaei, M. Renin-angiotensin system inhibitors and development of hepatocellular carcinoma: A systematic review and meta-analysis. Curr. Pharm. Des., 2020, 26(39), 5079-5085.
[http://dx.doi.org/10.2174/1381612826666200713165018] [PMID: 32660400]
[28]
Zhang, J.; Liu, J.; Chen, J.; Li, X.; Wu, Y.; Chen, H.; Wu, W.; Zhang, K.; Gu, L. Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: A systematic review and meta-analysis. Int. J. Clin. Exp. Med., 2015, 8(8), 12656-12660.
[PMID: 26550179]
[29]
Xie, Y.; Wang, M.; Xu, P.; Deng, Y.; Zheng, Y.; Yang, S.; Wu, Y.; Zhai, Z.; Zhang, D.; Li, N.; Wang, N.; Cheng, J.; Dai, Z. Association between antihypertensive medication use and breast cancer: A systematic review and meta-analysis. Front. Pharmacol., 2021, 12609901
[http://dx.doi.org/10.3389/fphar.2021.609901] [PMID: 34054514]
[30]
Cao, L.; Zhang, S.; Jia, C.M.; He, W.; Wu, L.T.; Li, Y.Q.; Wang, W.; Li, Z.; Ma, J. Antihypertensive drugs use and the risk of prostate cancer: A meta-analysis of 21 observational studies. BMC Urol., 2018, 18(1), 17.
[http://dx.doi.org/10.1186/s12894-018-0318-7] [PMID: 29514670]
[31]
Leung, P.S. The physiology of a local renin-angiotensin system in the pancreas. J. Physiol., 2007, 580(Pt 1), 31-37.
[http://dx.doi.org/10.1113/jphysiol.2006.126193] [PMID: 17218353]
[32]
Skipworth, J.R.; Szabadkai, G.; Olde Damink, S.W.; Leung, P.S.; Humphries, S.E.; Montgomery, H.E. Pancreatic renin-angiotensin sys-tems in health and disease. Aliment. Pharmacol. Ther., 2011, 34(8), 840-852.
[http://dx.doi.org/10.1111/j.1365-2036.2011.04810.x] [PMID: 21851372]
[33]
Leung, P.S.; Chan, W.P.; Wong, T.P.; Sernia, C. Expression and localization of the renin-angiotensin system in the rat pancreas. J. Endocrinol., 1999, 160(1), 13-19.
[http://dx.doi.org/10.1677/joe.0.1600013] [PMID: 9854172]
[34]
Kim, S.; Toyokawa, H.; Yamao, J.; Satoi, S.; Yanagimoto, H.; Yamamoto, T.; Hirooka, S.; Yamaki, S.; Inoue, K.; Matsui, Y.; Kwon, A.H. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Pancreas, 2014, 43(6), 886-890.
[http://dx.doi.org/10.1097/MPA.0000000000000125] [PMID: 24717824]
[35]
Arafat, H.A.; Gong, Q.; Chipitsyna, G.; Rizvi, A.; Saa, C.T.; Yeo, C.J. Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J. Am. Coll. Surg., 2007, 204(5), 996-1005.
[http://dx.doi.org/10.1016/j.jamcollsurg.2007.01.067] [PMID: 17481528]
[36]
Arnold, S.A.; Rivera, L.B.; Carbon, J.G.; Toombs, J.E.; Chang, C-L.; Bradshaw, A.D.; Brekken, R.A. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation. PLoS One, 2012, 7(2), e31384-e31384.
[http://dx.doi.org/10.1371/journal.pone.0031384] [PMID: 22348081]
[37]
Noguchi, R.; Yoshiji, H.; Ikenaka, Y.; Namisaki, T.; Kitade, M.; Kaji, K.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol. Rep., 2009, 22(2), 355-360.
[PMID: 19578777]
[38]
Gong, Q.; Davis, M.; Chipitsyna, G.; Yeo, C.J.; Arafat, H.A. Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas, 2010, 39(5), 581-594.
[http://dx.doi.org/10.1097/MPA.0b013e3181c314cd] [PMID: 20118823]
[39]
Masamune, A.; Hamada, S.; Kikuta, K.; Takikawa, T.; Miura, S.; Nakano, E.; Shimosegawa, T. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand. J. Gastroenterol., 2013, 48(5), 602-609.
[http://dx.doi.org/10.3109/00365521.2013.777776] [PMID: 23477656]
[40]
Kumar, V.; Boucher, Y.; Liu, H.; Ferreira, D.; Hooker, J.; Catana, C.; Hoover, A.J.; Ritter, T.; Jain, R.K.; Guimaraes, A.R. Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma. Transl. Oncol., 2016, 9(5), 431-437.
[http://dx.doi.org/10.1016/j.tranon.2016.07.004] [PMID: 27751347]
[41]
Khoshghamat, N.; Jafari, N.; Toloue-Pouya, V.; Azami, S.; Mirnourbakhsh, S.H.; Khazaei, M.; Ferns, G.A.; Rajabian, M.; Avan, A. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Life Sci., 2021, 270, 119118-119118.
[http://dx.doi.org/10.1016/j.lfs.2021.119118] [PMID: 33548284]
[42]
Chauhan, V.P.; Martin, J.D.; Liu, H.; Lacorre, D.A.; Jain, S.R.; Kozin, S.V.; Stylianopoulos, T.; Mousa, A.S.; Han, X.; Adstamongkonkul, P.; Popović, Z.; Huang, P.; Bawendi, M.G.; Boucher, Y.; Jain, R.K. Angiotensin inhibition enhances drug delivery and potentiates chemo-therapy by decompressing tumour blood vessels. Nat. Commun., 2013, 4, 2516-2516.
[http://dx.doi.org/10.1038/ncomms3516] [PMID: 24084631]
[43]
Fendrich, V.; Chen, N-M.; Neef, M.; Waldmann, J.; Buchholz, M.; Feldmann, G.; Slater, E.P.; Maitra, A.; Bartsch, D.K. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genet-ically engineered mouse model of pancreatic cancer. Gut, 2010, 59(5), 630-637.
[http://dx.doi.org/10.1136/gut.2009.188961] [PMID: 19880966]
[44]
Reddy, M.K.; Baskaran, K.; Molteni, A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc. Soc. Exp. Biol. Med., 1995, 210(3), 221-226.
[http://dx.doi.org/10.3181/00379727-210-43942]
[45]
Rhodes, D.R.; Ateeq, B.; Cao, Q.; Tomlins, S.A.; Mehra, R.; Laxman, B.; Kalyana-Sundaram, S.; Lonigro, R.J.; Helgeson, B.E.; Bhojani, M.S.; Rehemtulla, A.; Kleer, C.G.; Hayes, D.F.; Lucas, P.C.; Varambally, S.; Chinnaiyan, A.M. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. USA, 2009, 106(25), 10284-10289.
[http://dx.doi.org/10.1073/pnas.0900351106] [PMID: 19487683]
[46]
Foekens, J.A.; Look, M.P.; Bolt-de Vries, J.; Meijer-van Gelder, M.E.; van Putten, W.L.; Klijn, J.G. Cathepsin-D in primary breast cancer: Prognostic evaluation involving 2810 patients. Br. J. Cancer, 1999, 79(2), 300-307.
[http://dx.doi.org/10.1038/sj.bjc.6690048] [PMID: 9888472]
[47]
Jones, V.A.; McLaughlan, P.; Shorthouse, M.; Workman, E.; Hunter, J.O. Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome. Lancet, 1982, 2(8308), 1115-1117.
[http://dx.doi.org/10.1016/S0140-6736(82)92782-9] [PMID: 6128447]
[48]
Tandon, A.K.; Clark, G.M.; Chamness, G.C.; Chirgwin, J.M.; McGuire, W.L. Cathepsin D and prognosis in breast cancer. N. Engl. J. Med., 1990, 322(5), 297-302.
[http://dx.doi.org/10.1056/NEJM199002013220504] [PMID: 2296271]
[49]
Thorpe, S.M.; Rochefort, H.; Garcia, M.; Freiss, G.; Christensen, I.J.; Khalaf, S.; Paolucci, F.; Pau, B.; Rasmussen, B.B.; Rose, C. Associa-tion between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res., 1989, 49(21), 6008-6014.
[PMID: 2790815]
[50]
Tumminello, F.M.; Gebbia, N.; Pizzolanti, G.; Russo, A.; Bazan, V.; Leto, G. Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: A preliminary report. Oncology, 1995, 52(3), 237-242.
[http://dx.doi.org/10.1159/000227464] [PMID: 7715907]
[51]
Garcia, M.; Derocq, D.; Pujol, P.; Rochefort, H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene, 1990, 5(12), 1809-1814.
[PMID: 2284099]
[52]
Rochefort, H.; Capony, F.; Garcia, M.; Cathepsin, D. A protease involved in breast cancer metastasis. Cancer Metastasis Rev., 1990, 9(4), 321-331.
[http://dx.doi.org/10.1007/BF00049522] [PMID: 1965795]
[53]
Goldstein, B.; Trivedi, M.; Speth, R.C. Alterations in gene expression of components of the renin-angiotensin system and its related en-zymes in lung cancer. Lung Cancer Int., 2017, 20176914976
[http://dx.doi.org/10.1155/2017/6914976]
[54]
Imai, N.; Hashimoto, T.; Kihara, M.; Yoshida, S.; Kawana, I.; Yazawa, T.; Kitamura, H.; Umemura, S. Roles for host and tumor angioten-sin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab. Invest., 2007, 87(2), 189-198.
[http://dx.doi.org/10.1038/labinvest.3700504] [PMID: 17318197]
[55]
Suganuma, T.; Ino, K.; Shibata, K.; Kajiyama, H.; Nagasaka, T.; Mizutani, S.; Kikkawa, F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peri-toneal dissemination. Clin. Cancer Res., 2005, 11(7), 2686-2694.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-1946] [PMID: 15814650]
[56]
Doi, C.; Egashira, N.; Kawabata, A.; Maurya, D.K.; Ohta, N.; Uppalapati, D.; Ayuzawa, R.; Pickel, L.; Isayama, Y.; Troyer, D.; Takekoshi, S.; Tamura, M. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer, 2010, 10, 67.
[http://dx.doi.org/10.1186/1471-2407-10-67] [PMID: 20181281]
[57]
Uemura, H.; Hasumi, H.; Ishiguro, H.; Teranishi, J.; Miyoshi, Y.; Kubota, Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate, 2006, 66(8), 822-830.
[http://dx.doi.org/10.1002/pros.20407] [PMID: 16482568]
[58]
Ross, J.S.; Nazeer, T.; Figge, H.L.; Fisher, H.A.; Rifkin, M.D. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status. Am. J. Clin. Pathol., 1995, 104(1), 36-41.
[http://dx.doi.org/10.1093/ajcp/104.1.36] [PMID: 7541934]
[59]
Dolley-Hitze, T.; Jouan, F.; Martin, B.; Mottier, S.; Edeline, J.; Moranne, O.; Le Pogamp, P.; Belaud-Rotureau, M-A.; Patard, J-J.; Rioux-Leclercq, N.; Vigneau, C. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br. J. Cancer, 2010, 103(11), 1698-1705.
[http://dx.doi.org/10.1038/sj.bjc.6605866] [PMID: 21102591]
[60]
Delforce, S.J.; Lumbers, E.R.; Corbisier de Meaultsart, C.; Wang, Y.; Proietto, A.; Otton, G.; Scurry, J.; Verrills, N.M.; Scott, R.J.; Pringle, K.G. Expression of Renin-Angiotensin System (RAS) components in endometrial cancer. Endocr. Connect., 2017, 6(1), 9-19.
[http://dx.doi.org/10.1530/EC-16-0082] [PMID: 27956412]
[61]
Carl-McGrath, S.; Ebert, M.P.; Lendeckel, U.; Röcken, C. Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol. Ther., 2007, 6(8), 1218-1226.
[http://dx.doi.org/10.4161/cbt.6.8.4412] [PMID: 18059164]
[62]
Röcken, C.; Lendeckel, U.; Dierkes, J.; Westphal, S.; Carl-McGrath, S.; Peters, B.; Krüger, S.; Malfertheiner, P.; Roessner, A.; Ebert, M.P. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion poly-morphism. Clin. Cancer Res., 2005, 11(7), 2526-2530.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-1922] [PMID: 15814629]
[63]
Kanshin, E.; Wang, S.; Ashmarina, L.; Fedjaev, M.; Nifant’ev, I.; Mitchell, G.A.; Pshezhetsky, A.V. The stoichiometry of protein phos-phorylation in adipocyte lipid droplets: Analysis by N-terminal isotope tagging and enzymatic dephosphorylation. Proteomics, 2009, 9(22), 5067-5077.
[http://dx.doi.org/10.1002/pmic.200800861] [PMID: 19921680]
[64]
Egami, K.; Murohara, T.; Shimada, T.; Sasaki, K.; Shintani, S.; Sugaya, T.; Ishii, M.; Akagi, T.; Ikeda, H.; Matsuishi, T.; Imaizumi, T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest., 2003, 112(1), 67-75.
[http://dx.doi.org/10.1172/JCI16645] [PMID: 12840060]
[65]
Podhajcer, O.L.; Bover, L.; Bravo, A.I.; Ledda, M.F.; Kairiyama, C.; Calb, I.; Guerra, L.; Capony, F.; Mordoh, J. Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J. Invest. Dermatol., 1995, 104(3), 340-344.
[http://dx.doi.org/10.1111/1523-1747.ep12665371] [PMID: 7860998]
[66]
Fujita, M.; Hayashi, I.; Yamashina, S.; Fukamizu, A.; Itoman, M.; Majima, M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis, 2005, 26(2), 271-279.
[http://dx.doi.org/10.1093/carcin/bgh324] [PMID: 15637093]
[67]
Clere, N.; Corre, I.; Faure, S.; Guihot, A.L.; Vessières, E.; Chalopin, M.; Morel, A.; Coqueret, O.; Hein, L.; Delneste, Y.; Paris, F.; Henrion, D. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogene-sis. Int. J. Cancer, 2010, 127(10), 2279-2291.
[http://dx.doi.org/10.1002/ijc.25234] [PMID: 20143398]
[68]
Kosugi, M.; Miyajima, A.; Kikuchi, E.; Horiguchi, Y.; Murai, M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin. Cancer Res., 2006, 12(9), 2888-2893.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2213] [PMID: 16675585]
[69]
Chen, X.; Meng, Q.; Zhao, Y.; Liu, M.; Li, D.; Yang, Y.; Sun, L.; Sui, G.; Cai, L.; Dong, X. Angiotensin II type 1 receptor antagonists in-hibit cell proliferation and angiogenesis in breast cancer. Cancer Lett., 2013, 328(2), 318-324.
[http://dx.doi.org/10.1016/j.canlet.2012.10.006] [PMID: 23092556]
[70]
Oh, E.; Kim, J.Y.; Cho, Y.; An, H.; Lee, N.; Jo, H.; Ban, C.; Seo, J.H. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. Biochim. Biophys. Acta, 2016, 1863(6 Pt A), 1071-1081.
[http://dx.doi.org/10.1016/j.bbamcr.2016.03.010] [PMID: 26975580]
[71]
Peiling Yang, S.; Ngeow, J.Familial non-medullary thyroid cancer: Unraveling the genetic maze. Endocr. Relat. Cancer, 2016, 23(12), R577-R595.
[http://dx.doi.org/10.1530/ERC-16-0067] [PMID: 27807061]
[72]
Hashemzehi, M.; Naghibzadeh, N.; Asgharzadeh, F.; Mostafapour, A.; Hassanian, S.M.; Ferns, G.A.; Cho, W.C.; Avan, A.; Khazaei, M. The therapeutic potential of losartan in lung metastasis of colorectal cancer. EXCLI J., 2020, 19, 927-935.
[PMID: 32665776]
[73]
Seow, C.H.; Leber, J.M.; Ee, H.C.; Yusoff, I.F. Survey of consent practices for inpatient colonoscopy and endoscopic retrograde cholangi-opancreatography at a tertiary referral center. J. Gastroenterol. Hepatol., 2006, 21(8), 1340-1345.
[http://dx.doi.org/10.1111/j.1440-1746.2006.04152.x] [PMID: 16872320]
[74]
Matysiak, Z.E.; Ochędalski, T.; Piastowska-Ciesielska, A.W. The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer. Gynecol. Endocrinol., 2015, 31(1), 1-6.
[http://dx.doi.org/10.3109/09513590.2014.958991] [PMID: 25231075]
[75]
Chen, Y-H.; Huang, C-H.; Lu, H-I.; Chen, C-H.; Huang, W-T.; Hsieh, M-J.; Rau, K-M.; Chang, A.Y.; Lin, W-C.; Li, S-H. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma. J. Renin Angiotensin Aldosterone Syst., 2015, 16(4), 1185-1192.
[http://dx.doi.org/10.1177/1470320314535275] [PMID: 24961505]
[76]
Arrieta, O.; Guevara, P.; Escobar, E.; García-Navarrete, R.; Pineda, B.; Sotelo, J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br. J. Cancer, 2005, 92(7), 1247-1252.
[http://dx.doi.org/10.1038/sj.bjc.6602483] [PMID: 15785746]
[77]
Nissen, S.E. Angiotensin-receptor blockers and cancer: Urgent regulatory review needed. Lancet Oncol., 2010, 11(7), 605-606.
[http://dx.doi.org/10.1016/S1470-2045(10)70142-X] [PMID: 20542469]
[78]
Kinoshita, J.; Fushida, S.; Harada, S.; Yagi, Y.; Fujita, H.; Kinami, S.; Ninomiya, I.; Fujimura, T.; Kayahara, M.; Yashiro, M.; Hirakawa, K.; Ohta, T. Local angiotensin II-generation in human gastric cancer: Correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int. J. Oncol., 2009, 34(6), 1573-1582.
[http://dx.doi.org/10.3892/ijo_00000287] [PMID: 19424575]
[79]
Roman, Y.M.; Dominguez, M.C.; Easow, T.M.; Pasupuleti, V.; White, C.M.; Hernandez, A.V. Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: A systematic review and meta-analysis of randomized controlled trials. Int. J. Obes., 2019, 43(10), 2017-2027.
[http://dx.doi.org/10.1038/s41366-018-0204-0] [PMID: 30206335]
[80]
Renziehausen, A.; Wang, H.; Rao, B.; Weir, L.; Nigro, C.L.; Lattanzio, L.; Merlano, M.; Vega-Rioja, A.; Del Carmen Fernandez-Carranco, M.; Hajji, N.; Matin, R.; Harwood, C.; Li, S.; Sim, V.R.; O’Neill, K.; Evans, A.; Thompson, A.; Szlosarek, P.; Fleming, C.; Stebbing, J.; Proby, C.; Tzakos, A.G.; Syed, N.; Crook, T. The Renin Angiotensin System (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. Oncogene, 2019, 38(13), 2320-2336.
[http://dx.doi.org/10.1038/s41388-018-0563-y] [PMID: 30478450]
[81]
Tawinwung, S.; Ninsontia, C.; Chanvorachote, P. Angiotensin II increases cancer stem cell-like phenotype in lung cancer cells. Anticancer Res., 2015, 35(9), 4789-4797.
[PMID: 26254369]
[82]
Beyazit, F.; Ayhan, S.; Celik, H.T.; Gungor, T. Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch. Gynecol. Obstet., 2015, 292(2), 415-420.
[http://dx.doi.org/10.1007/s00404-015-3661-x] [PMID: 25693759]
[83]
Peterson, B.K.; Weber, J.N.; Kay, E.H.; Fisher, H.S.; Hoekstra, H.E. Double digest RADseq: An inexpensive method for de novo SNP discovery and genotyping in model and non-model species. PLoS One, 2012, 7(5)e37135
[http://dx.doi.org/10.1371/journal.pone.0037135] [PMID: 22675423]
[84]
Ahmadian, E.; Khosroushahi, A.Y.; Eftekhari, A.; Farajnia, S.; Babaei, H.; Eghbal, M.A. Novel angiotensin receptor blocker, azilsartan induces oxidative stress and NFkB-mediated apoptosis in hepatocellular carcinoma cell line HepG2. Biomed. Pharmacother., 2018, 99, 939-946.
[http://dx.doi.org/10.1016/j.biopha.2018.01.117] [PMID: 29710494]
[85]
Uemura, H.; Ishiguro, H.; Nakaigawa, N.; Nagashima, Y.; Miyoshi, Y.; Fujinami, K.; Sakaguchi, A.; Kubota, Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther., 2003, 2(11), 1139-1147.
[PMID: 14617787]
[86]
Scott-Emuakpor, J.; Allot, E.; Johnson, S.A.; Howard, L.E.; Macias, E.; Freedland, S.J.; Gurley, S.B. Angiotensin receptor signaling and prostate tumor growth in mice. J. Exp. Ther. Oncol., 2017, 11(2), 107-115.
[PMID: 28976133]
[87]
Funao, K.; Matsuyama, M.; Kawahito, Y.; Sano, H.; Chargui, J.; Touraine, J-L.; Nakatani, T.; Yoshimura, R. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol. Rep., 2008, 20(2), 295-300.
[PMID: 18636189]
[88]
Hii, S.I.; Nicol, D.L.; Gotley, D.C.; Thompson, L.C.; Green, M.K.; Jonsson, J.R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer, 1998, 77(6), 880-883.
[http://dx.doi.org/10.1038/bjc.1998.145] [PMID: 9528828]
[89]
Miyajima, A.; Kosaka, T.; Asano, T.; Asano, T.; Seta, K.; Kawai, T.; Hayakawa, M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res., 2002, 62(15), 4176-4179.
[PMID: 12154013]
[90]
Isobe, A.; Takeda, T.; Sakata, M.; Miyake, A.; Yamamoto, T.; Minekawa, R.; Nishimoto, F.; Oskamoto, Y.; Walker, C.L.; Kimura, T. Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation. Hum. Reprod., 2008, 23(2), 440-446.
[http://dx.doi.org/10.1093/humrep/dem247] [PMID: 17993476]

Rights & Permissions Print Cite
Article Metrics
49
2
© 2024 Bentham Science Publishers | Privacy Policy